Investigation of the Therapeutic Efficacy of Codelivery of psiRNA–Vascular Endothelial Growth Factor and pIL-4 into Chitosan Nanoparticles in the Breast Tumor Model
Authors:
- 1 March 2014
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 103 (3) , 785-795
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Therapeutic plasmid DNA versus siRNA delivery: Common and different tasks for synthetic carriersJournal of Controlled Release, 2012
- Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics?Biotechnology Advances, 2011
- Chitosan as a carrier for targeted delivery of small interfering RNAInternational Journal of Pharmaceutics, 2010
- Non-viral nanosystems for systemic siRNA deliveryPharmacological Research, 2010
- Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancerCancer Letters, 2008
- Effect of interleukin-4 on vascular endothelial growth factor production in rheumatoid synovial fibroblastsClinical and Experimental Immunology, 2006
- Progress towards in Vivo Use of siRNAsMolecular Therapy, 2006
- Angiogenesis in human cancer: implications in cancer therapyEuropean Journal of Internal Medicine, 2003
- Inducible shRNA expression for application in a prostate cancer mouse modelNucleic Acids Research, 2003
- Clinical significance of determination of surrogate markers of angiogenesis in breast cancerCritical Reviews in Oncology/Hematology, 2001